Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Suraxavir Marboxil (GP681) in Healthy Subjects
NCT04729764Phase 1Completed
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of suraxavir marboxil in influenza (5 arms), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoints: Pharmacokinetic parameter at 12 days, Incidence of adverse events as a measure of safety and tolerability at 12 days and 1 more. Started Aug 2020; status: completed.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04729764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729764.